APA (7th ed.) Citation

D, M., A, P., D, P., S, P., N, K., P, A., & V, P. (2026). Anti-CD38 targeted carfilzomib-loaded hybrid nanocomposites for multiple myeloma therapy: Cytotoxicity and biodistribution. Discover oncology, 17(1), . https://doi.org/10.1007/s12672-026-04516-0

Chicago Style (17th ed.) Citation

D, Mishra, Patel A, Panjwani D, Patel S, Kushwaha N, Ahlawat P, and Patel V. "Anti-CD38 Targeted Carfilzomib-loaded Hybrid Nanocomposites for Multiple Myeloma Therapy: Cytotoxicity and Biodistribution." Discover Oncology 17, no. 1 (2026). https://doi.org/10.1007/s12672-026-04516-0.

MLA (9th ed.) Citation

D, Mishra, et al. "Anti-CD38 Targeted Carfilzomib-loaded Hybrid Nanocomposites for Multiple Myeloma Therapy: Cytotoxicity and Biodistribution." Discover Oncology, vol. 17, no. 1, 2026, https://doi.org/10.1007/s12672-026-04516-0.